AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.
Arlocabtagene autoleucel met response and complete-response endpoints in patients already exposed to immunomodulators, proteasome inhibitors, anti-CD38 treatment and BCMA therapy, positioning GPRC5D as a possible next CAR T target after increasingly crowded myeloma treatment sequences.
Europe has approved teclistamab plus daratumumab after MajesTEC-3 showed an 83.4% reduction in progression or death and a significant overall-survival advantage versus established regimens.
Discover how wearable injectors could reshape multiple myeloma treatment, clinic capacity and the competitive battle between Sarclisa and daratumumab.
Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!
Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.
Biomarkers can speed drug approvals, but weak validation can haunt sponsors. FDA and EMA are tightening the path from signal to endpoint.
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.